The HLA class I molecules identified serologically as HLA-B27 are highly associated with ankylosing spondylitis and related human disorders. All known HLA-B27 amino acid sequences contain a cysteine residue at position 67; no other published HLA class I sequence contains a cysteine within the hypervariable region of the a, domain, which extends from amino acid residues 63-84. To investigate the role of this cysteine residue in the antigenic structure of HLA-B27, we isolated a genomic clone encoding a molecule of the HLA-B27.1 subtype and performed oligonucleotide-directed mutagenesis to convert the cysteine at position 67 to a tyrosine. When transfected into mouse L cells, both the wild-type and Cys67 -) Tyr67 mutant B27 genes directed the synthesis and surface expression of molecules reactive with the monomorphic anti-HLA class I antibody W6/32. However, only the L cells transfected with the wild-type B27 gene reacted with the anti-B27 antibody ME1; L cells transfected with the mutant B27 were completely unreactive with this antibody. Experiments with hybrid exons created from the HLA-B27 and HLA-A2 genes yielded results consistent with the mapping of the ME1 epitope to the B27 a, domain. A second anti-B27 antibody, GS145.2, also showed markedly reduced binding to the Cys67 -Tyr67 mutant. These studies document the importance of the unique Cys67 residue in the antigenic structure of HLA-B27.
Introduction
Human class I major histocompatibility molecules are glycoproteins expressed on the surfaces of nucleated somatic cells. Each consists of two noncovalently associated polypeptide chains: a 44,000-Mr polymorphic heavy chain encoded by one of the multiallelic HLA-A, B, and C loci of the human MHC on chromosome 6 , and an invariant 12,000-Mr light chain, ,32-microglobulin, encoded on chromosome 15 (1) . The HLAencoded heavy chains are organized in three extracellular do-mains designated as a I (amino acid residues 1-90), a2 (residues 91-182), and a3 (residues 183-274); a hydrophobic transmembrane region; and an intracytoplasmic carboxy-terminal domain. Virtually all of the polymorphic variation within each locus and most of the variation among the three serologically identified class I HLA loci reside in the nucleotide and corresponding amino acid sequences of the a, and 2 domains. The polymorphism of the class I HLA molecules is thought to be related to their function as restriction elements for the specific recognition of foreign antigens by T lymphocytes.
The allelic products ofthe HLA-A, B, and C loci have been traditionally identified by alloantisera. However, several serologically well-defined alloantigenic specificities are divisible further into subtypes on the basis of a few amino acid differences in the aI and/or a2 domains (2) (3) (4) (5) (6) . HLA-B27, as defined by alloantisera, identifies a group of at least six HLA-B locus products that share the B27 allospecificity (5, 6) .
Serologically defined HLA-B27 is associated with a group of idiopathic inflammatory human diseases, including ankylosing spondylitis (AS),' reactive arthritis, and acute anterior uveitis (7, 8) . The strongest association is with AS; in Caucasian populations, the prevalence of HLA-B27 in the general population is -8%, whereas in patients with primary AS it exceeds 90%. Attempts to correlate the incidence of AS with one or more of the B27 subtypes have not been successful; AS apparently is associated with most, if not all, of the B27 subtypes (7, 9) .
This study was undertaken to begin to identify the features of the HLA-B27 sequence that correlate with the serologically defined B27 allospecificity and with disease association. One striking feature unique to B27, and shared by all six B27 subtypes whose sequences are known, is the presence of an unpaired cysteine residue at amino acid position 67 in the a, domain (6) . In this communication, it is demonstrated that substitution of this cysteine with a tyrosine, the residue found at position 67 in the closely related allele HLA-B7 (10), eliminates the epitopes defined by two MAb that react with all known B27 subtypes.
Methods
Isolation of genomic clones encoding HLA-B27 and HLA-B7. Genomic DNA was isolated as previously described ( 11) from peripheral blood leukocytes of an AS patient who was homozygous for HLA-B27. DNA was digested with Eco RI; 6-7-kb fragments were ligated into the bacteriophage vector X gt 0, packaged, and used to create a size-se-lected library in Escherichia coli strain C600 hfl-(Gigapack; Stratagene Cloning Systems, La Jolla, CA). The library was screened (12) with a probe, pHLA-l. 1, that is relatively specific for the HLA-B locus under stringent conditions (13) . 18 positive clones were obtained; 3 were plaque-purified and subcloned into pUCl9. One clone, pD. l-B27 (Fig. 1) , was selected for the experiments described in this communication. It was confirmed to encode a product ofthe B27.1 subtype (5, 14, 15) by extensive restriction mapping, DNA sequencing, and serologic identification of the gene product expressed in transfected cells. In a similar manner, a size-selected library was constructed from an HLA-B7' individual, and p12.1-B7, a genomic clone encoding HLA-B7, was isolated and similarly characterized.
Site-directed mutagenesis. A 2.2-kb Eco RI-Avr II fragment encoding exons 1-3 of pD. l-B27 was subcloned into Eco RI/Xba I-cut Ml3mpl8 to produce the recombinant mB27mO-RA, and a 2.3-kb Avr II-Pst I fragment encoding exons 4-8 was subcloned into Xba I/Pst I-cut pUCl9 to produce pB27-AP. Mutagenesis of mB27mO-RA was carried out as described in detail by Zoller and Smith (16), using the mutagenic 18-base oligonucleotide described in Fig. 2 . Mutant recombinants in E. coli strain TGl were identified by differential plaque hybridization with 32P-end-labeled mutagenic oligonucleotide. One mutant, mB27ml-RA, was selected for further use (see Results). Three reconstituted B27 genes were then created: the mB27ml-RA insert was isolated as an Eco RI-Hinc II fragment (the Hinc II site residing in the M13 polylinker 3' to the insert) and ligated into Eco RI-Sma I-cut pB27-AP, to create the mutant pB27ml-RP. Alternative wild-type (pB27-R'P) and mutant (pB27ml-R'P) reconstituted B27 genes were produced by ligating the 2.0-kb Eco RI-Stu I fragments of pD.1-B27 and mB27ml-RA, respectively, into Eco RI/Sma I-cut pB27-AP. In these latter two constructs, 200 bp was deleted from the 3' end of intron 3 (see Fig. 1 ).
Exchange ofKpn Ifragments between HLA-B27 and HLA-A2. The gene encoding HLA-A2, contained on a 5.1-kb Hind III fragment and termed pHLA-2 (17), was the gift of Dr. H. T. Orr, University of Minnesota. We took advantage ofthe fact that the genes for HLA-B27 and HLA-A2 each contain two Kpn I sites, both located in the two genes at homologous positions in exon 3 (Fig. 1) . The 212-bp sequences bounded by these two sites encode amino acids 114-182 in both gene products; 10 of these amino acids differ between the two sequences (Fig. 3) . The two 212-bp Kpn I fragments were isolated, respectively, from the HLA-A2 gene subcloned into pUC9, and the pD.l-B27 gene subcloned into pUC13; they were then reciprocally ligated into the opposite Kpn I-restricted recombinant plasmids to create the respective constructs, pB27-KKA2 and pA2-KKB27. The orientations of the exchanged, religated 212-bp fragments were confirmed by restriction mapping.
DNA sequencing. Sequencing of the exons encoding the wild-type and mutant B27 a, and a2 domains was accomplished by the dideoxy chain termination method (18) using 20-base oligonucleotide primers complementary to sequences flanking or contained within the exons. Oligonucleotides were custom-synthesized by solid phase phosphoramidite chemistry with a DNA synthesizer (380A; Applied Biosystems, Inc., Foster City, CA). They were purified by electrophoresis in 20% polyacrylamide/7.5 M urea gels. Sequence data analysis was performed with the software package Microgenie (Beckman Instruments, Inc., Spinco Div., Palo Alto, CA).
Southern blotting. Southern blot hybridization of genomic DNA was carried out as previously described (11) . Two probes were used: a 1.4-kb B7 cDNA (10), which hybridizes with broad specificity to human and mouse class I MHC genes; and an Xba I-Eco RI fragment containing the extreme 3' 700 bp of the pD. I -B27 gene ( Fig. 1 After initial transfection of L cells with pD.l-B27, 55% of the HAT-resistant cell population was positive with the anti-B27 antibody ME 1. The cells were then subjected to two rounds of positive selection, and the resulting population was used for subsequent experiments. Some of the other transfected cell populations were used for analysis without sorting of the positive cells, as indicated in Results.
Results
Site-directed mutagenesis. A putative mutant M1 3 clone, mB27ml-RA, was confirmed by DNA sequencing to contain the intended mutation in exon 2 (Fig. 4) . The remainder of exons 2 and 3 of mB27ml-RA were also sequenced and shown not to vary from the wild-type B27 sequence. Plasmid constructs containing reconstituted mutant or wild-type genes - 
with the B27. 1 (Fig. 6 B) , probably because oflower than usual efficiency oftransfection; however, the binding of MEl to this population was actually below background and therefore truly negative. Like MEl, GS145.2 reacted strongly with the wild-type B27 transfectant but very poorly with the Cys67 Tyr67 mutant product (Fig. 7) . These results indicate that GS145.2, like MEl, recognizes a B27 epitope that is abolished by the nonconservative substitution at amino acid position 67.
To test whether MEl also reacts with sites outside the a, domain, its binding to cells transfected with genes containing hybrid third exons was assessed. MEl bound to cells transfected with the construct pB27-KKA2 (Fig. 6 D) (25) with this topographic region on HLA-B7; however, the pattern of its reactivity with other HLA-B antigens indicates that its specificity is distinct from that of ME 1.
Of particular note is the potential relevance of these findings to the unique association of HLA-B27 with human disease. Although it remains formally possible that this association is due to an allele in tight linkage disequilibrium with HLA-B27, there is now substantial indirect evidence that the HLA-B27 molecule itself is directly involved in disease pathogenesis (7, 9) . The six B27 subtypes identified by isoelectric focusing have been sequenced at the protein level (5, 6 ) and shown to display distinctive cytolytic T cell (CTL)-defined epitopes (5, 30, 31) . The amino acid differences among the B27 variants that account for differences in CTL recognition have been mapped to positions 59, 74, 77, 80, 81, 114, 116, and 152. Because class I MHC molecules serve as recognition elements for CTL, and because only a small minority of HLA-B27' individuals ever develop B27-associated disease (7, 32, 33) , efforts have been made to identify CTL-defined B27 subtypes that correlate specifically with disease. However, no significant correlation has been found between AS and any particular subtype of B27 (7, 9, 34) , and AS remains most highly correlated with serologically defined B27, just as originally reported in 1973 (9, 35, 36) .
Much ofthe sequence variability among HLA-A, B, and C molecules occurs in amino acids 62-83 in the a, domain and 94-116 in the a2 domain (Fig. 3) . Among the known HLA class I sequences, B27-unique residues shared by all the B27 subtypes are found at three positions: Cys67, Lys70, and Asn97 (1, 5, 6, 37) . Our study has demonstrated the importance of Cys67 in two B27 serologic specificities. The x ray crystallographic model of the three-dimensional structure of HLA-A2 (27, 28) predicts that residue 67 makes contact with the ligand in the antigen-binding groove. It was demonstrated that a peptide fragment distinct from the HLA-A2 molecule occupied the antigen-binding groove in the crystallized A2, and it was postulated that such peptide fragments may be found constitutively in class I MHC molecules (29) . Participation of HLA-B27 in disease pathogenesis may result from covalent interaction between the Cys67 sulfhydryl group and one or more endogenous or exogenous ligands. With regard to potential exogenous ligands, studies by Geczy et al. (38, 39) have suggested that a B27-associated structure on leukocytes can be modified by bacterial products, and that this modification correlates with the presence of disease in B27+ subjects. It would be of interest to know whether the B27 Cys67 residue is involved in this modification process.
